SINOPHARM- HYT (Inactivated) Vaccine Price

Overview

Welcome to Dwaey, specifically on SINOPHARM- HYT (Inactivated) Vaccine page.
This medicine contains an important and useful components, as it consists of
SARS-CoV-2 Vaccine (Vero Cell), Inactivated 6.5 Unit /0.5 ml SARS-CoV-2 Vaccine (Vero Cell), Inactivated 6.5 Unit /0.5 mlis available in the market in concentration

Name

Atenolol + Nifedipine

Precaution

The combination of atenolol (a beta-blocker) and nifedipine (a calcium channel blocker) is commonly used for managing hypertension, angina, and certain cardiovascular conditions. However, caution is necessary due to the complementary but potentially synergistic effects of these medications. Atenolol lowers heart rate and reduces myocardial contractility by blocking beta-1 receptors, while nifedipine, particularly the immediate-release formulation, can cause a sudden drop in blood pressure by relaxing smooth muscle. The combination of these two drugs can lead to excessive hypotension, especially when starting therapy or when adjusting dosages. Close monitoring of blood pressure is essential to avoid symptomatic hypotension, dizziness, or syncope. Patients with preexisting bradycardia or heart block should be closely monitored, as atenolol can exacerbate these conditions. In patients with a history of heart failure, this combination may require careful titration to avoid worsening symptoms of heart failure. Additionally, while nifedipine’s vascular effects can help in reducing hypertension, the risk of reflex tachycardia (compensatory increase in heart rate) may be mitigated by the heart rate-lowering effects of atenolol. The combination should be used with caution in elderly patients, who are more likely to experience dizziness or orthostatic hypotension. Pregnant and breastfeeding women should consult their healthcare provider before using this combination, as both drugs are categorized as Pregnancy Category C, indicating potential risks to the fetus.

Indication

Atenolol and nifedipine are used together primarily for the management of hypertension (high blood pressure) and angina (chest pain). Atenolol is a beta-1 selective blocker that reduces heart rate and myocardial contractility, which lowers blood pressure and reduces the heart's oxygen demand. Nifedipine, a calcium channel blocker, relaxes the smooth muscles of blood vessels, leading to vasodilation and a subsequent decrease in blood pressure. This combination is especially useful in patients who require dual mechanisms to control their blood pressure and prevent angina episodes. The dual approach can provide superior control in patients who may not respond adequately to monotherapy. Nifedipine, particularly in its extended-release form, is also used to manage Raynaud’s phenomenon, a condition involving blood vessel spasm in the fingers and toes, although this is an off-label use. The combination therapy may be prescribed in patients who have stable angina or essential hypertension with a need for more comprehensive cardiovascular risk management. Off-label uses might include the treatment of certain arrhythmias or in patients with pulmonary hypertension, but these applications should be considered based on clinical judgment.

Contra indication

The combination of atenolol and nifedipine is contraindicated in patients with known hypersensitivity to either of the drugs. Specifically, it should not be used in patients with certain heart conditions, such as second- or third-degree heart block, severe bradycardia, or sick sinus syndrome, unless they have a functioning pacemaker. Both drugs can exacerbate these conditions; atenolol can slow the heart rate, and nifedipine, especially in its immediate-release form, can cause sudden hypotension, potentially worsening heart failure or arrhythmias. For patients with severe hypotension (systolic blood pressure < 90 mmHg), the combination should be avoided as it can further lower blood pressure and cause dizziness or fainting. Nifedipine should also be avoided in patients with severe aortic stenosis, as vasodilation may exacerbate the obstruction and impair coronary perfusion. Both atenolol and nifedipine should be avoided during acute or uncontrolled heart failure, as their combined effects on heart rate and vascular tone can worsen symptoms. Pregnant and breastfeeding women should consult their healthcare provider due to the potential risks to the fetus or neonate, as both medications pass into breast milk and may have adverse effects on fetal or neonatal development.

Side Effect

Common side effects associated with the combination of atenolol and nifedipine include dizziness, fatigue, and lightheadedness, particularly when standing up quickly, due to their blood pressure-lowering effects. Other cardiovascular side effects may include bradycardia (slow heart rate), palpitations, and hypotension, especially during the initial phases of treatment or with dose adjustments. In some patients, nifedipine can cause peripheral edema (swelling of the feet and ankles) due to its vasodilatory effects, which is a common side effect of calcium channel blockers. Gastrointestinal side effects such as nausea, constipation, and heartburn may occur with nifedipine. Atenolol may also cause cold extremities, shortness of breath, or erectile dysfunction in some individuals. Less commonly, patients may experience a rash, joint pain, or changes in mood, particularly with long-term use. Serious side effects include severe hypotension, heart block, or signs of heart failure worsening, particularly in patients with underlying cardiac conditions. If symptoms like severe dizziness, chest pain, or shortness of breath occur, patients should seek immediate medical attention. Regular monitoring of blood pressure and heart rate is important to detect adverse effects early.

Pregnancy Category ID

4

Mode of Action

The combination of atenolol and nifedipine works synergistically to lower blood pressure and reduce the workload on the heart. Atenolol is a selective beta-1 adrenergic blocker, which decreases heart rate and myocardial contractility by blocking the effects of norepinephrine and epinephrine on beta-1 receptors. This results in a reduction in heart rate, blood pressure, and myocardial oxygen demand, making it particularly useful in conditions like hypertension and angina. Nifedipine, a calcium channel blocker, exerts its effect by inhibiting calcium ions from entering smooth muscle cells and cardiac myocytes. This inhibition of calcium influx causes relaxation and dilation of blood vessels, leading to a decrease in vascular resistance and blood pressure. Additionally, nifedipine reduces the heart's workload by improving coronary artery perfusion, making it effective in treating angina. The combination of these two medications provides complementary mechanisms of action—atenolol reducing the heart rate and nifedipine causing vasodilation—resulting in effective management of both hypertension and angina.

Interaction

Atenolol and nifedipine can interact with several other medications, which may either enhance the risk of side effects or reduce the effectiveness of treatment. When used together, these two drugs may have an additive hypotensive effect, which could lead to excessive lowering of blood pressure. This is particularly concerning when initiating therapy or adjusting dosages. Other antihypertensive medications, such as ACE inhibitors, angiotensin II receptor blockers (ARBs), or diuretics, can amplify this effect, increasing the risk of orthostatic hypotension or dizziness. Calcium channel blockers like nifedipine can also interact with medications that affect the metabolism of calcium, such as digoxin, which may lead to an increased risk of bradycardia or heart block. Atenolol’s heart rate-reducing effects can counteract reflex tachycardia induced by nifedipine, making the combination effective in preventing tachycardia caused by sudden blood pressure drops. However, this interaction can be risky if not properly monitored. Additionally, the combination should be used cautiously with other drugs that can slow the heart rate, such as antiarrhythmics or digoxin, as the risk of bradycardia is heightened. Alcohol consumption can amplify the hypotensive effects of both drugs, increasing the risk of dizziness, syncope, and falls. Monitoring of blood pressure and heart rate is essential when taking these drugs together, and dose adjustments may be needed based on patient response.

Pregnancy Category Note

Information not available

Adult Dose

The recommended starting dose for the combination of atenolol and nifedipine varies depending on the patient's condition and blood pressure response. For hypertension, the initial dose typically starts with 50 mg of atenolol once daily and 30-60 mg of nifedipine extended-release once daily. The dose may be gradually increased based on the patient’s response, with a typical maximum dose of 100 mg of atenolol and 120 mg of nifedipine per day. For angina, doses are similar, with atenolol starting at 50 mg daily and nifedipine starting at 30 mg daily. The maximum recommended dose of atenolol is 100 mg per day, and nifedipine can go up to 120 mg per day, depending on the formulation. These doses should be adjusted based on individual tolerability and response. The drugs can be taken orally with or without food, but the extended-release formulation of nifedipine should not be crushed or chewed. Monitoring of blood pressure and heart rate is necessary to adjust the doses to the optimal therapeutic level.

Child Dose

The use of the atenolol and nifedipine combination in children is generally not recommended as a first-line treatment for hypertension or other cardiovascular conditions due to limited pediatric data. However, in cases of pediatric hypertension or arrhythmias, individual dosing may be considered. For children, atenolol is typically dosed based on weight, with a starting dose of 0.5 mg/kg once daily, up to a maximum of 1 mg/kg daily. For nifedipine, the typical dose in children is 0.25 mg/kg to 0.5 mg/kg once daily, with a maximum dose of 2 mg/kg daily. These medications should be used with caution, and close monitoring for side effects, particularly on heart rate and blood pressure, is essential. Pediatric patients should be regularly assessed for potential adverse effects, and therapy should be adjusted accordingly to ensure safety and efficacy.

Renal Dose

In patients with renal impairment, particularly those with severe renal dysfunction (creatinine clearance < 30 mL/min), adjustments to the doses of atenolol and nifedipine may be necessary. Atenolol is primarily excreted unchanged in the urine, so patients with renal impairment may experience increased drug levels, which can enhance the risk of bradycardia and hypotension. The dose of atenolol should be reduced in these patients, typically to 25 mg daily, with regular monitoring of heart rate and blood pressure. Nifedipine is also metabolized by the liver, but its excretion can be affected in patients with severe renal dysfunction. In such cases, careful monitoring of blood pressure and renal function is essential, and the dose of nifedipine should be reduced accordingly. Regular serum creatinine and BUN levels should be monitored to ensure proper renal function during therapy. If renal impairment is severe, alternative antihypertensive therapy may be considered.

Administration

Information not available